Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14729105 | 0.90 | GPR119 (0.53) | GPR119PIK3CADGAT1 | |
| SCHEMBL14729106 | 0.89 | GPR119 (0.51) | GPR119 | |
| SCHEMBL14729111 | 0.88 | GPR119 (0.55) | GPR119HRH3DGAT1 | |
| SCHEMBL14729202 | 0.87 | GPR119 (0.48) | GPR119HRH3DGAT1 | |
| SCHEMBL14729109 | 0.83 | ALDH1A1 (0.50) | GPR119PIK3CDPIK3CAPIK3CBPI4KA | |
| SCHEMBL14729110 | 0.83 | GPR119 (0.49) | GPR119 | |
| SCHEMBL2591328 | 0.82 | GPR119 (0.58) | GPR119 | |
| SCHEMBL14729112 | 0.82 | GPR119 (0.56) | GPR119 | |
| SCHEMBL14729103 | 0.82 | PIK3CD (0.41) | GPR119HRH3PIK3CDPIK3CAPIK3CB | |
| SCHEMBL14729107 | 0.82 | HRH3 (0.39) | GPR119HRH3PIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940716-B2 | Bicyclic heteroaryl compounds as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| US-20130053345-A1 | BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053345-A1 | BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS | GPR119, GPR139, GPR4 | GPR119 1/4885HRH3 522/4885PIK3CD 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.